Edition:
India

Motif Bio PLC (MTFB.OQ)

MTFB.OQ on NASDAQ Stock Exchange Capital Market

9.25USD
15 Dec 2017
Change (% chg)

$-0.10 (-1.07%)
Prev Close
$9.35
Open
$9.05
Day's High
$9.25
Day's Low
$9.00
Volume
1,330
Avg. Vol
1,505
52-wk High
$13.70
52-wk Low
$5.36

Summary

Name Age Since Current Position

Richard Morgan

69 Non-Executive Chairman of the Board

Graham Lumsden

55 Chief Executive Officer, Executive Director

Robert Dickey

2017 Chief Financial Officer

Rajesh Shukla

2016 Vice President - Clinical Operations

Robert Bertoldi

61 2016 Executive Director

David Huang

41 Chief Medical Officer

Stephen Austin

Company Secretary

Craig Albanese

2017 Non-Executive Director

Charlotta Ginman-Jones

52 Non-Executive Director

Jonathan E Gold

42 Non-Executive Director

Zaki Hosny

66 Non-Executive Director

Mary Polan

73 Non-Executive Director

Bruce Williams

57 Non-Executive Director

Biographies

Name Description

Richard Morgan

Mr. Richard Cecil Eversfield Morgan is Non-Executive Chairman of the Board of the company. He has been Chairman of the Company and is also Chief Executive Officer of Amphion. Amphion is the successor firm to VennWorks LLC and Amphion Capital Partners LLC, which Mr Morgan also co-founded. Over the course of his career, Mr Morgan has been directly involved in the start-up and development of more than 30 companies in the information technology, healthcare and biotechnology industries. These include MediSense, Sequus Pharmaceuticals, Celgene, Quidel and Vortech Data. Prior to this Mr Morgan spent 15 years with Schroders plc as a board member and head of the Schroders Strategy Group, which he founded. Mr Morgan was a co-founder of Celgene Corporation, and held a board position with the company from 1987 to 2008. Mr Morgan currently serves as Chairman of four other Amphion Partner Companies (Axcess, FireStar, Private Markets and WellGen) and is also a director of DataTern.

Graham Lumsden

Mr. Graham George Lumsden is Chief Executive Officer, Executive Director of the company. He is responsible for all aspects of the strategy, management, and operations of the Company. Prior to joining the Company, Mr Lumsden was a senior executive at Merck & Co., Inc. where he held commercial leadership positions in multi-billion dollar worldwide businesses. Mr Lumsden has a proven record of success leading change and delivering results in subsidiary and global leadership positions, including new product launches, pre-clinical and clinical development, regulatory strategy, IP strategy and litigation, and strategic sales and marketing. Mr Lumsden is a member of the Royal College of Veterinary Surgeons (MRCVS), holds a postgraduate diploma from the Chartered Institute of Marketing (MCIM) and is a dual citizen of the UK and US.

Robert Dickey

Mr. Robert Dickey, IV is Chief Financial Officer of the Company. Mr. Dickey is an accomplished financial professional with senior leadership experience in private and public healthcare companies. Prior to joining Motif Bio, he was CFO at Tyme Technologies Inc., a NASDAQ-listed clinical stage oncology company. Robert previously held senior leadership positions at NeoStem, Inc. (now known as Caladrius Biosciences Inc.), Hemispherx Biopharma Inc., Stemcyte Inc., Locus Pharmaceuticals Inc. and Protarga Inc. Mr. Dickey began his career as an Investment Banker at Lehman Brothers and Legg Mason Wood Walker Inc.

Rajesh Shukla

Dr. Rajesh B. Shukla is the Vice President - Clinical Operations of the Company. Dr. Shukla is an accomplished clinical operations professional with extensive experience in Research, Development and Medical Affairs. He joins the Company from ACORDA Therapeutics where he was Senior Medical Director Clinical Development and Medical Affairs. He was previously Head, R&D Global Clinical and Medical Affairs at Pfizer Global Established Products, reporting to the Division Head. Dr. Shukla earned his BS in Biochemistry from Lehigh University in Bethlehem, PA and a PhD from Carnegie-Mellon University in Pittsburgh, PA.

Robert Bertoldi

Mr. Robert Joseph Bertoldi is Executive Director of the company. He has been Chief Financial Officer of Amphion and was a founder President and continues to be the Chief Financial Officer of Amphion Capital Partners LLC (the predecessor of Amphion) and VennWorks LLC. Mr Bertoldi is also a general partner of Amphion Partners LLC (formerly known as Wolfensohn Partners, LP). Prior to that, Mr Bertoldi served as Chief Financial Officer for James D. Wolfensohn, Inc. and Hambro America Inc. Mr Bertoldi currently serves as a director of three other Amphion Partner Companies, m2m, WellGen and Axcess and is also a director of DataTern. Mr Bertoldi began his career at KPMG and left as a manager in the investment services department. Mr Bertoldi obtained a B.A. in Accounting and Economics from Queens College, New York in 1976 and became a Certified Public Accountant in 1978. He is a member of the AICPA and NYSCPA.

David Huang

Dr. David Huang M.D. Ph.D. is Chief Medical Officer of the company. He is a senior pharmaceutical research executive, and the former Chief Medical Officer at ContraFect Corporation where he had the responsibility for the development of biologic anti-infectives, including bacteriophage lysins and monoclonal antibodies. Dr Huang also led drug development groups in anti-infectives at Pfizer and Boehringer-Ingelheim. Dr Huang has 15 years of clinical, academic and research experience in medicine and in the subspecialty of infectious diseases. He has served as a faculty member at Baylor College of Medicine and currently as an adjunct Assistant Professor at Rutgers New Jersey Medical School. His research interests include bacteriology and virology, especially the epidemiology, pathogenesis and treatment of multidrug resistant organisms. He is well versed in the design, execution and close out of Phase I–III clinical trials for both antibacterials and antiviral agents. Dr Huang completed his medical school at the University of Texas at Houston Medical School, and completed his internship and residency in internal medicine at the University of Texas Southwestern and fellowship in infectious diseases at Baylor of Medicine.

Stephen Austin

Craig Albanese

Dr. Craig T. Albanese Non-Executive Director of the Company. Dr. Albanese has 25 years of clinical and administrative experience focusing on children and women's health, primarily in the Stanford Children's Hospital, New-York Presbyterian Hospital, Morgan Stanley Children's Hospital and the Sloane Hospital for Women. He has had a distinguished clinical career to date having published 161 peer review articles, contributed 57 book chapters, and risen to Professor of Surgery in Paediatrics, Obstetrics and Gynecology. He has combined his clinical career with success in hospital administrative positions where he has had a pivotal role in setting up networks of physicians, support, and educational services across a number of hospitals and medical institutions to provide integrated clinical and support services for increasing numbers of patients in a very cost-effective way.

Charlotta Ginman-Jones

Ms. Charlotta Ginman-Jones is Non-Executive Director of the company. She has substantial experience in financial and operational management gained during her career in investment banking and global telecommunications. Joining Ernst & Young and later appointed to senior roles with JP Morgan, Deutsche Bank and UBS, Ms Ginman-Jones progressed to director of finance at Nokia Corporation, overseeing a number of acquisitions and led the successful sale of Nokia’s luxury mobile phone division, Vertu Corporation, to a private equity group. During the last two years she has been appointed as a non-executive director onto the boards of Wolfson Microelectronics plc (until its sale to Cirrus Logic in August 2014), Kromek Group plc, an AIM quoted company, where she also acts as chair of the audit committee as well as onto the board of Pacific Assets Trust plc, Polar Capital Technology Trust plc, and Consort Medical plc, all UK based listed companies. A qualified chartered accountant in England and Wales, Ms Ginman-Jones also holds an MSc. in Economics from the Swedish School of Economics and Business Administration in Helsinki. Ms Ginman-Jones resides in London but is a Finnish national.

Jonathan E Gold

Mr. Jonathan Gold is Non-Executive Director of the company. He is a Managing Director of JEG Capital LLC, a family office and asset manager. Previously he was a Portfolio Manager for the Federated Kaufmann Funds from 2004 until 2012. The Federated Kaufmann Funds are growth mutual funds which currently have approximately US$10 billion in assets under management. Prior to that Mr Gold was a partner in Amphion Capital Partners LLC (the predecessor of Amphion) and Wolfensohn Partners (originally affiliates of James D. Wolfensohn Inc) where he was active in financing and growing early stage life sciences and information technology companies from 1995 to 2004. Early in his career, Mr Gold was a financial analyst for Prudential’s Realty Group, which managed equity and mortgage real estate investments. Mr Gold received his Bachelor of Science and MBA in Finance from New York University’s Stern School of Business.

Zaki Hosny

Mr. Zaki Hosny is Non-Executive Director of the company. He is an independent consultant to life sciences companies. Mr Hosny spent most of his career at Merck & Co. in marketing and general management positions around the world, including management responsibility for the company’s business in major markets in Europe. He also held senior marketing roles with worldwide responsibility for cardiovascular and other franchises, and was closely involved in the clinical development of some of the company’s major products. Mr Hosny was Chief Executive Officer of Motif, Inc. between 2006 and 2013, and Deputy Chairman of its Board of Directors. Mr Hosny continues to serve on the Board of Directors for Motif, Inc. Mr Hosny is currently a Senior Advisor to the Albright Stonebridge Group, a strategic consultancy firm based in Washington, DC, Business Development Advisor to ClinTec International Ltd, a clinical research organisation based in Glasgow, Scotland, and a consultant to Harel Consulting of New Jersey and Mettle Consulting Limited of the UK. Mr Hosny is based in Princeton, New Jersey and is a graduate of Cambridge University with an M.A. in History and Law. He has joint UK and US citizenship and is fluent in French.

Mary Polan

Dr. Mary Lake Polan is Non-Executive Director of the company. She has been served as the chair of the Department of Obstetrics and Gynaecology at the Stanford University School of Medicine and is currently a Clinical Professor in the Department of Obstetrics, Gynaecology and Reproductive Medicine at the Yale University School of Medicine. Dr Polan specialises in reproductive endocrinology and infertility and hormonal issues related to gynaecology patients and menopause. She received her bachelor’s degree from Connecticut College and her Ph.D. in Molecular Biophysics and Biochemistry and M.D. from Yale University. Dr Polan completed her residency and Reproductive Endocrine Fellowship in the Department of Obstetrics and Gynaecology at the Yale University School of Medicine. Dr Polan received her M.P.H. (Maternal and Child Health Programme) from the University of California, Berkeley. Dr Polan served on the board of Wyeth Pharmaceuticals prior to its acquisition by Pfizer and currently serves on the board of Quidel Corp, San Diego, CA and on the boards of several privately held life sciences companies. She chairs a Scientific Advisory Board in Women’s Health for the Proctor and Gamble Company and several other advisory boards of private life sciences companies. She is also a Managing Director of Golden Seeds, an angel investing group which invests in women led companies. Dr Polan’s research has involved ovarian and urologic function with many publications in both areas. She is a member of the Institute of Medicine of the National Academy of Sciences and has served on a number of NIH and university committees. She has a long-standing interest in women’s health research and has been actively involved in international public health.

Bruce Williams

Mr. Bruce Andrew Williams is Non-Executive Director of the company. He has experience in the pharmaceutical and biotech industries. Mr Williams was an executive director of Ortho Biotech where he led the marketing of this Johnson & Johnson subsidiary’s lead product Procrit (epoetin alfa) from pre-launch to its fifth year on the market, realising in excess of US$1 billion of revenue. Mr Williams was previously Senior Vice President of Sales and Marketing at Celgene Corporation where he built the company’s commercial and distribution infrastructure to support the launch of its first product Thalomid (thalidomide). Mr Williams was previously Senior Vice President, Sales and Marketing at Genta Incorporated where he led the negotiation of a licensing and co-development/co-marketing agreement with Aventis for the company’s lead product. The company realised over US$300 million in proceeds from this agreement. Mr Williams currently serves on the boards of Motif, Inc. and Afaxys Incorporated.